bpc 157 post knee surgery Meniscus Tear Healing Evidence Stable Gastric Pentadecapeptide BPC 157

Phase 2 trial data (Jastreboff et al., NEJM 2023) demonstrated average weight reductions of approximately 1724% over 48 weeks notably higher than currently approved GLP-1 receptor agonists such as semaglutide, though direct comparisons are limited by differences in trial populations and designs

BOOK NOW Embrace the Future You The team at Southeast Sculpting + Rejuvenation is committed to helping patients look and feel their best

Lauren Fitzgerald breaks down the truth about peptidesdispelling the fear spread by big pharma and explaining why they are safe, effective, and backed by over a century of therapeutic research

Independent replication by separate teams is limited